CBD Benefits & Current Research

One of the studies cited on the original page examined CBD before a simulated public-speaking task. Participants receiving 300 mg reported less anxiety than the placebo group, while the lower and higher doses did not show the same pattern.

Animal research has also investigated antidepressant-like effects, but animal findings cannot establish that CBD treats depression in humans. Larger, well-controlled human trials are still needed.

This is one of the clearest areas of cannabinoid medicine. In 2018, the U.S. FDA approved Epidiolex, a prescription form of purified CBD, for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

That approval relates to a specific prescription medicine used under medical supervision. It should not be interpreted as evidence that ordinary retail CBD products can be substituted for prescribed epilepsy treatment.

The existing page cites a small case series in which CBD was used alongside standard psychiatric care in people with PTSD. Most participants reported reduced symptom severity, but the study involved only eleven people and did not establish CBD as a stand-alone treatment.

PTSD care may involve psychological therapy, medicines or other evidence-based interventions. CBD research in this area remains preliminary.

Research cited on the original page investigated whether CBD could reduce cue-induced craving and anxiety in people with heroin use disorder. Some favourable effects were reported during the study period.

This remains an investigational area. Opioid use disorder is a serious medical condition and should be treated with established addiction services, medical supervision and evidence-based therapies.

The original page discusses research involving combinations of THC and CBD for spasticity in people with amyotrophic lateral sclerosis (ALS). This evidence concerns cannabinoid combinations rather than CBD alone.

Findings around symptom relief do not indicate that cannabinoids slow, reverse or cure ALS.

Cannabinoids have been studied in several pain settings. The existing page references Sativex, a prescription oromucosal medicine containing THC and CBD, as well as a small topical-CBD study involving peripheral neuropathy.

These studies use different formulations and patient groups, so they cannot be generalised to every CBD oil, balm or cream. Evidence for pain management remains formulation- and condition-specific.

The existing page cites laboratory, animal and small human studies examining CBD in relation to glucose-related pathways, inflammation and insulin-related hormones.

These findings are preliminary. CBD should not be described as a natural treatment for diabetes and must not replace insulin, prescribed medicines, dietary management or professional diabetes care.

Preclinical research has investigated CBD in relation to inflammatory, oxidative and neurological pathways relevant to diseases such as multiple sclerosis, Parkinson’s disease and Alzheimer’s disease.

Preclinical findings do not demonstrate that CBD prevents or treats these diseases in people. Clinical evidence remains insufficient for broad treatment claims.

Studies cited on the existing page include a trial of a THC:CBD medicine in rheumatoid arthritis and a later study of synthetic transdermal CBD for osteoarthritis-related knee pain.

Results have not been uniformly positive. Some outcomes improved while others did not differ significantly from placebo, reinforcing the need for larger and better-controlled clinical trials.